GLP-1 drugs are being studied in people with lipedema, a condition involving disproportionate fat accumulation, most often in the legs. Studies of fat and lean mass during GLP-1 weight loss measure overall body composition. Lipedema research needs to measure effects in affected tissue and on symptoms such as pain and swelling.[1][3]
What the survey found
In the 2026 online survey (n = 2,719), about 55% of respondents were current users of a GLP-1 or dual GIP/GLP-1 drug, most often tirzepatide. Among respondents who reported why they used these medicines, 67.2% cited weight management and 19.3% cited lipedema symptoms as the main reason. Current users reported median physical health scores of 42.3 versus 39.1 among never-users, and mental health scores of 44.9 versus 40.8.[1]
Participants answered the questionnaire once and recalled changes since starting medication. The groups may have differed before treatment, and the survey could not determine how much of the difference, if any, the medication caused.[1]
What the small clinical reports measured
A 2025 case series described five women with lipedema and insulin resistance who received exenatide, some alongside lifestyle changes. A November 2026 report followed five women with lipedema and excess body weight through diet and exercise changes. Four later added tirzepatide. In the latter series, lower-limb measurements and subcutaneous fat thickness generally decreased, with variation between participants.[2][3]